In this study, Berman and colleagues show that a subpopulation of C. albicans cells can tolerate antifungal drug treatment, which contributes to persistent infection.

Two studies discover new avenues that could be explored for the novel therapeutic intervention of fungal infections.

A new study shows that drug combination therapy results in fitness trade-offs in Candida albicans.

A fungal pathogen evolves transient resistance to an antimicrobial drug using a novel RNAi-mediated pathway that generates reversible epimutations.